Clinical Trials

Selimetry Trial

October 26th, 2018

The Selimetry trial has now closed. There is a new trial underway for patients whose thyroid cancer is no longer responsive the RAI treatment. Your oncologist will have to ensure that you fit into the criteria necessary for the trial. You can be referred to any of the following centres . Bristol Haematology and Oncology […]


The Latest Clinical Trial for Thyroid Cancer is well under way

August 30th, 2017

The IoN trial is the only national clinical study of thyroid cancer in the UK. Funded by Cancer Research UK, it aims to show whether certain patients with well-differentiated thyroid cancer need radioiodine ablation or not, when they have already had their thyroid gland removed and are on hormone treatment. The clinicians have been searching […]


National IoN trial update

May 9th, 2014

The latest UK Thyroid Cancer Clinical Trial ION is well underway with more than 110 patients who are already taking part in this important study of thyroid cancer. The UK HiLo study results were reported in the top medical journal, theNew England Journal of Medicine, in May 2012. It showed that selected patients with well-differentiated […]


New Clinical Trial for patients with Advanced Medullary Thyroid Cancer

April 9th, 2012

An International, Randomised, Double-Blind, Two-Arm Study to Evaluate the Safety and Efficacy of Vandetanib 150 and 300mg/day in Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma with Progressive or Symptomatic Disease 10 countries, 34 sites plus seven back-up sites Hopefully five UK centres – Cardiff, Christie, Royal Marsden, Barts and Newcastle – will […]


HiLo clinical trial for Thyroid Cancer – Findings

January 9th, 2012

Allan Hackshaw, Deputy Director of Cancer Research UK, comments: “Recommended treatment for most patients with differentiated thyroid cancer is surgery followed by a high administered dose of 3.7 GBq (100mCi) radioiodine ablation. However, a lower dose (1.1 GBq or 30 mCi) has advantages including a shorter stay in hospital isolation and lower risk of side […]